嗜铬细胞瘤

Kunz PL, Reidy-Lagunes D, Anthony LB, et al; North American Neuroendocrine Tumor Society. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013 May;42(4):557-77.

• 全文
• 摘要

Plouin PF, Amar L, Dekkers OM, et al; Guideline Working Group. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016 May;174(5):G1-10.

• 全文
• 摘要

Pacak K, Linehan WM, Eisenhofer G, et al. Recent advances in genetics, diagnosis, localization and treatment of pheochromocytoma. Ann Intern Med. 2001 Feb 20;134(4):315-29.

• 全文
• 摘要

Pacak KL, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):92-102.

• 摘要

Adjallé R, Plouin PF, Pacak K, et al. Treatment of malignant pheochromocytoma. Horm Metab Res. 2009 Sep;41(9):687-96.

• 摘要

1.  Lenders JW, Eisenhofer G, Manelli M, et al. Phaeochromocytoma. Lancet. 2005 Aug 20-26;366(9486):665-75.

• 摘要

2.  Mazzaglia PJ. Hereditary pheochromocytoma and paraganglioma. J Surg Oncol. 2012 Oct 1;106(5):580-5.

• 摘要

3.  Canu L, Rapizzi E, Zampetti B, et al. Pitfalls in genetic analysis of pheochromocytomas/paragangliomas - case report. J Clin Endocrinol Metab. 2014 Jul;99(7):2321-6.

• 摘要

4.  Martucci VL, Pacak K. Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer. 2014 Jan-Feb;38(1):7-41.

• 全文
• 摘要

5.  Lloyd RV, Osamura RY, Klöppel G, et al, eds. WHO classification of tumours of endocrine organs: WHO classification of tumours. 4th ed., Vol. 10. Lyon, France: International Agency of research on Cancer (IARC); 2017.

6.  Lam AK. Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours. Endocr Pathol. 2017 Sep;28(3):213-27.

• 摘要

7.  Bravo EL. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev. 1994 Jun;15(3):356-68.

• 摘要

8.  Sinnott B, Wu S, Sarne D, et al. Presentation of an unsuspected pheochromocytoma as acute aortic valvular insufficiency and diabetes mellitus type 2. Endocrinologist. 2006 Nov/Dec;16(6):335-9.

• 全文

9.  Towards Optimized Practice Program (Canada). Laboratory endocrine testing guidelines: pheochromocytoma. Jan 2008; reviewed May 2014 [internet publication].

• 全文

10.  Sutton MG, Sheps SG, Lie JT. Prevalence of clinically unsuspected pheochromocytomas: review of a 50-year autopsy series. Mayo Clin Proc. 1981 Jun;56(6):354-60.

• 摘要

11.  Yeo H, Roman S. Pheochromocytoma and functional paraganglioma. Curr Opin Oncol. 2005 Jan;17(1):13-8.

• 摘要

12.  Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002 May 9;346(19):1459-66.

• 摘要

13.  Whalen RK, Althausen AF, Daniels GH. Extra-adrenal pheochromocytoma. J Urol. 1992 Jan;147(1):1-10.

• 摘要

14.  Barontini M, Levin G, Sanso G. Characteristics of pheochromocytoma in a 4- to 20-year-old population. Ann N Y Acad Sci. 2006 Aug;1073:30-7.

• 摘要

15.  Eisenhofer G. Screening for pheochromocytomas and paragangliomas. Curr Hypertens Rep. 2012 Apr;14(2):130-7.

• 摘要

16.  Bravo EL. Pheochromocytoma: new concepts and future trends. Kidney Int. 1991 Sep;40(3):544-56.

• 摘要

17.  Pattarino F, Bouloux PM. The diagnosis of malignancy in phaeochromocytoma. Clin Endocrinol (Oxf). 1996 Feb;44(2):239-41.

• 摘要

18.  Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005 Dec 1;23(34):8812-8.

• 摘要

19.  Reisch N, Peczkowska M, Januszewicz A, et al. Pheochromocytoma: presentation, diagnosis, and treatment. J Hypertens. 2006 Dec;24(12):2331-9.

• 摘要

20.  Parenti G, Zampetti B, Rapizzi E, et al. Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma. J Oncol. 2012;2012:872713.

• 全文
• 摘要

21.  Marini F, Falchetti A, Del Monte F, et al. Multiple endocrine neoplasia type 2. Orphanet J Rare Dis. 2006 Nov 14;1:45.

• 全文
• 摘要

22.  Pomares FJ, Canas R, Rodriguez JM, et al. Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma. Clin Endocrinol (Oxf). 1998 Feb;48(2):195-200.

• 摘要

23.  Maher ER. Von Hippel-Lindau disease. Curr Mol Med. 2004 Dec;4(8):833-42.

• 摘要

24.  Riccardi VM. Von Recklinghausen neurofibromatosis. N Engl J Med. 1981 Dec 31;305(27):1617-27.

• 摘要

25.  Astuti D, Douglas F, Lennard TW, et al. Germline SDHD mutation in familial phaeochromocytoma. Lancet. 2001 Apr 14;357(9263):1181-2.

• 摘要

26.  Sinnott B, Hatipoglu B. Adrenal incidentaloma in pregnancy. Endocrinologist. 2005 Jul/Aug;15(4):205-8.

• 全文

27.  Kudva YC, Young WF Jr, Thompson GB, et al. Adrenal incidentaloma: an important component of the clinical presentation spectrum of benign sporadic adrenal pheochromocytoma. Endocrinologist. 1999 Mar;9(2):77-80.

• 全文

28.  Singh PK, Buch HN. Adrenal incidentaloma: evaluation and management. J Clin Pathol. 2008 Nov;61(11):1168-73.

• 摘要

29.  Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. J Clin Endocrinol Metab. 2000 Feb;85(2):637-44.

• 全文
• 摘要

30.  Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med. 2003 Mar 4;138(5):424-9.

• 全文
• 摘要

31.  Tabarin A, Bardet S, Bertherat J, et al; French Society of Endocrinology Consensus. Exploration and management of adrenal incidentalomas. Ann Endocrinol (Paris). 2008 Dec;69(6):487-500.

• 摘要

32.  Zeiger MA, Thompson GB, Duh QY, et al. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas: executive summary of recommendations. Endocr Pract. 2009 Jul-Aug;15(5):450-3.

• 摘要

33.  Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev. 2003 Aug;24(4):539-53.

• 全文
• 摘要

34.  Kunz PL, Reidy-Lagunes D, Anthony LB, et al; North American Neuroendocrine Tumor Society. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013 May;42(4):557-77.

• 全文
• 摘要

35.  Sawka AM, Jaeschke R, Singh RJ, et al. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 2003 Feb;88(2):553-8.

• 全文
• 摘要

36.  Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002 Mar 20;287(11):1427-34.

• 全文
• 摘要

37.  Eisenhofer G, Golstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab. 2003 Jun;88(6):2656-66.

• 全文
• 摘要

38.  Lenders JW, Duh QY, Eisenhofer G, et al; Endocrine Society. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42.

• 全文
• 摘要

39.  Grossrubatscher E, Dalino P, Vignati F, et al. The role of chromogranin A in the management of patients with pheochromocytoma. Clin Endocrinol. 2006 Sep;65(3):287-93.

• 摘要

40.  Plouin PF, Amar L, Dekkers OM, et al; Guideline Working Group. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol. 2016 May;174(5):G1-10.

• 全文
• 摘要

41.  Bornstein SR, Gimenez-Roqueplo AP. Genetic testing in pheochromocytoma: increasing importance for clinical decision making. Ann N Y Acad Sci. 2006 Aug;1073:94-103.

• 摘要

42.  Rana HQ, Rainville IR, Vaidya A. Genetic testing in the clinical care of patients with pheochromocytoma and paraganglioma. Curr Opin Endocrinol Diabetes Obes. 2014 Jun;21(3):166-76.

• 摘要

43.  Hampel H, Bennett RL, Buchanan A, et al. A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med. 2015 Jan;17(1):70-87.

• 全文
• 摘要

44.  Havekes B, King K, Lai EW, et al. New imaging approaches to phaeochromocytomas and paragangliomas. Clin Endocrinol (Oxf). 2010 Feb;72(2):137-45.

• 全文
• 摘要

45.  Manger WM, Gifford RW. Pheochromocytoma. J Clin Hypertens (Greenwich). 2002 Jan-Feb;4(1):62-72.

• 摘要

46.  Manger WM, Eisenhofer G. Pheochromocytoma: diagnosis and management update. Curr Hypertens Rep. 2004 Dec;6(6):477-84.

• 摘要

47.  Pacak K, Del Rivero J. Pheochromocytoma. In: De Groot LJ, Chrousos G, Dungan K, et al, eds. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000.

• 全文
• 摘要

48.  Terzolo M, Ali A, Pia A, et al. Cyclic Cushing's syndrome due to ectopic ACTH secretion by an adrenal pheochromocytoma. J Endocrinol Invest. 1994 Dec;17(11):869-74.

• 摘要

49.  Bayraktar F, Kebapcilar L, Kocdor MA, et al. Cushing's syndrome due to ectopic CRH secretion by adrenal pheochromocytoma accompanied by renal infarction. Exp Clin Endocrinol Diabetes. 2006 Sep;114(8):444-7.

• 摘要

50.  Stenström G, Sjöström L, Smith U. Diabetes mellitus in phaeochromocytoma: fasting blood glucose levels before and after surgery in 60 patients with phaeochromocytoma. Acta Endocrinol (Copenh). 1984 Aug;106(4):511-5.

• 摘要

51.  Smith SL, Slappy AL, Fox TP, et al. Pheochromocytoma producing vasoactive intestinal peptide. Mayo Clin Proc. 2002 Jan;77(1):97-100.

• 摘要

52.  Bravo EL, Gifford RW Jr. Pheochromocytoma. Endocrinol Metab Clin North Am. 1993 Jun;22(2):329-41.

• 摘要

53.  Martin SS, Karra R, Mark DB. Pheochromocytoma presenting as a fever of unknown origin. Am J Med. 2011;124:e5-6.

• 摘要

54.  Sawka AM, Jaeschke R, Singh RJ, et al. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab. 2003 Feb;88(2):553-8.

• 全文
• 摘要

55.  Václavík J, Stejskal D, Lacnák B, et al. Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients. J Hypertens. 2007 Jul;25(7):1427-31.

• 摘要

56.  Drenou B, Le Tulzo Y, Caulet-Maugendre S, et al. Pheochromocytoma and secondary erythrocytosis: role of tumor erythropoietin secretion. Nouv Rev Fr Hematol. 1995;37(3):197-9.

• 摘要

57.  Sjoberg RJ, Simcic KJ, Kidd GS. The clonidine suppression test for pheochromocytoma: a review of its utility and pitfalls. Arch Intern Med. 1992 Jun;152(6):1193-7.

• 摘要

58.  Pacak K, Linehan WM, Eisenhofer G, et al. Recent advances in genetics, diagnosis, localization and treatment of pheochromocytoma. Ann Intern Med. 2001 Feb 20;134(4):315-29.

• 全文
• 摘要

59.  Jacobson AF, Deng H, Lombard J, et al. 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab. 2010 Jun;95(6):2596-606.

• 全文
• 摘要

60.  Sarathi VL, Lila AR, Bandgar TR, et al. Pheochromocytoma and pregnancy: a rare but dangerous combination. Endocr Pract. 2010 Mar-Apr;16(2):300-9.

• 摘要

61.  Schulz V. Clinical pharmacokinetics of nitroprusside, cyanide, thiosulphate and thiocyanate. Clin Pharmacokinet. 1984 May-Jun;9(3):239-51.

• 摘要

62.  Kocak S, Aydintug S, Canakci N. Alpha blockade in preoperative preparation of patients with pheochromocytomas. Int Surg. 2002 Jul-Sep;87(3):191-4.

• 摘要

63.  Nicholson JP Jr, Vaughn ED Jr, Pickering TG, et al. Pheochromocytoma and prazosin. Ann Int Med. 1983 Oct;99(4):477-9.

• 摘要

64.  Prys-Roberts C, Farndon JR. Efficacy and safety of doxazosin for perioperative management of patients with phaeochromocytoma. World J Surg. 2002 Aug;26(8):1037-42.

• 摘要

65.  Tada K, Okuda T, Yamashita K. Three cases of malignant pheochromocytoma treated with cyclophosphamide, vincristine and dacarbazine combination chemotherapty and alpha-methyl-p-tyrosine to control hypercatecholaminemia. Horm Res. 1998;49(6):295-7.

• 摘要

66.  Cryer PE. Diseases of the sympathochromaffin system. In: Felig P, Frohman LA, eds. Endocrinology and metabolism, 4th ed. New York: McGraw-Hill; 2001:525-51.

67.  Petri BJ, van Eijck CH, de Herder WW, et al. Phaeochromocytomas and sympathetic paragangliomas. Br J Surg. 2009 Dec;96(12):1381-92.

• 全文
• 摘要

68.  Kaye DR, Storey BB, Pacak K, et al. Partial adrenalectomy: underused first line therapy for small adrenal tumors. J Urol. 2010 Jul;184(1):18-25.

• 摘要

69.  Kinney MA, Narr BJ, Warner MA. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth. 2002 Jun;16(3):359-69.

• 摘要

70.  Assalia A, Gagner M. Laparoscopic adrenalectomy. Br J Surg. 2004 Oct;91(10):1259-74.

• 摘要

71.  Brandao LF, Autorino R, Laydner H, et al. Robotic versus laparoscopic adrenalectomy: a systematic review and meta-analysis. Eur Urol. 2014 Jun;65(6):1154-61.

• 摘要

72.  Plouin PF, Duclos JM, Soppelsa F, et al. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J Clin Endocrinol Metab. 2001 Apr;86(4):1480-6.

• 全文
• 摘要

73.  Pacak KL, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab. 2007 Feb;3(2):92-102.

• 摘要

74.  Akiba M, Kodama T, Ito Y, et al. Hypoglycemia induced by excessive rebound secretion of insulin after removal of pheochromocytoma. World J Surg. 1990 May-Jun;14(3):317-24.

• 摘要

75.  Adjallé R, Plouin PF, Pacak K, et al. Treatment of malignant pheochromocytoma. Horm Metab Res. 2009 Sep;41(9):687-96.

• 摘要

76.  Scholz T, Eisenhofer G, Pacak K, et al. Clinical review: Current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab. 2007 Apr;92(4):1217-25.

• 摘要

77.  Edström Elder E, Hjelm Skog AL, Höög A, et al. The management of benign and malignant pheochromocytoma and abdominal paraganglioma. Eur J Surg Oncol. 2003 Apr;29(3):278-83.

• 摘要

78.  Shapiro B, Gross MD, Shulkin B. Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrinol Metab. 2001 Dec;12(10):469-75.

• 摘要

79.  Pacak K, Fojo T, Goldstein DS, et al. Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma. J Natl Cancer Inst. 2001 Apr 18;93(8):648-9.

• 全文
• 摘要

80.  Hadoux J, Favier J, Scoazec JY, et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer. 2014 Dec 1;135(11):2711-20.

• 摘要

81.  Yip L, Lee JE, Shapiro SE. Surgical management of hereditary pheochromocytoma. J Am Coll Surg. 2004 Apr;198(4):525-34.

• 摘要

82.  Lebuffe G, Dosseh ED, Tek G, et al. The effect of calcium channel blockers on outcome following the surgical treatment of phaechromocytomas and paragangliomas. Anaesthesia. 2005 May;60(5):439-44.

• 摘要

83.  Proye C, Thevenin D, Cecat P, et al. Exclusive use of calcium channel blockers in preoperative and intraoperative control of pheochromocytomas: hemodynamics and free catecholamine assays in ten consecutive patients. Surgery. 1989 Dec;106(6):1149-54.

• 摘要

84.  Kizer JR, Koniaris LS, Edelman JD, et al. Pheochromocytoma crisis, cardiomyopathy, and hemodynamic collapse. Chest. 2000 Oct;118(4):1221-3.

• 摘要

85.  Radtke WE, Kazmier FJ, Rutherford BD, et al. Cardiovascular complications of pheochromocytoma crisis. Am J Cardiol. 1975 May;35(5):701-5.

• 摘要

86.  Steinsapir J, Carr AA, Prisant LM, et al. Metyrosine and pheochromocytoma. Arch Intern Med. 1997 Apr 28;157(8):901-6.

• 摘要

87.  Amar L, Servais A, Gimenez-Roqueplo AP, et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab. 2005 Apr;90(4):2110-6.

• 全文
• 摘要

88.  Averbuch SD, Steakley CS, Young RC, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med. 1988 Aug 15;109(4):267-73.

• 摘要

89.  Fitzgerald PA, Goldsby RE, Huberty JP, et al. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann NY Acad Sci. 2006 Aug;1073:465-90.

• 摘要

90.  Eisenhofer G, Bornstein SR, Brouwers FM, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer. 2004 Sep;11(3):423-36.

• 全文
• 摘要

91.  Huang KH, Chung SD, Chen SC, et al. Clinical and pathological data of 10 malignant pheochromocytomas: long-term follow up in a single institution. Int J Urol. 2007 Mar;14(3):181-5.

• 摘要

92.  Ohji H, Sasagawa I, Iciyanagi O, et al. Tumor angiogenesis and Ki-67 expression in phaeochromocytoma. BJU Int. 2001 Mar;87(4):381-5.

• 摘要

93.  Tan SG, Koay CK, Chan ST. The use of vasopressin to treat catecholamine-resistant hypotension after pheochromocyoma removal. Anaesth Intensive Care. 2002 Aug;30(4):477-80.

• 摘要

94.  Khorram-Manesh A, Ahlman H, Nilsson O, et al. Long-term outcome of a large series of patients surgically treated for pheochromocytoma. J Intern Med. 2005 Jul;258(1):55-66.

• 摘要

95.  Amar L, Lussey-Lepoutre C, Lenders JW, et al. Management of endocrine disease: Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis. Eur J Endocrinol. 2016 Oct;175(4):R135-45.

• 全文
• 摘要

96.  Bernini GP, Vivaldi MS, Argenio GF, et al. Frequency of pheochromocytoma in adrenal incidentalomas and utility of the glucagon test for the diagnosis. J Endocrinol Invest. 1997 Feb;20(2):65-71.

• 摘要